Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Eversept Partners LP

Eversept Partners LP decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 39.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,097 shares of the biopharmaceutical company’s stock after selling 6,623 shares during the quarter. Eversept Partners LP’s holdings in Regeneron Pharmaceuticals were worth $7,794,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Capitolis Liquid Global Markets LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.7% during the 4th quarter. Capitolis Liquid Global Markets LLC now owns 80,000 shares of the biopharmaceutical company’s stock worth $61,750,000 after purchasing an additional 5,000 shares during the period. Cinctive Capital Management LP grew its stake in shares of Regeneron Pharmaceuticals by 227.5% during the 4th quarter. Cinctive Capital Management LP now owns 6,343 shares of the biopharmaceutical company’s stock worth $4,896,000 after purchasing an additional 4,406 shares during the period. Claro Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 22.4% during the 4th quarter. Claro Advisors Inc. now owns 557 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 102 shares during the period. Guggenheim Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 6.2% during the 4th quarter. Guggenheim Capital LLC now owns 44,918 shares of the biopharmaceutical company’s stock worth $34,671,000 after purchasing an additional 2,610 shares during the period. Finally, DV Equities LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $110,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.1%

Shares of NASDAQ:REGN opened at $607.93 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $503.25 and a 1 year high of $821.11. The firm has a market capitalization of $64.27 billion, a price-to-earnings ratio of 14.81, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The business’s 50 day moving average price is $683.13 and its 200-day moving average price is $734.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm posted $8.22 EPS. The business’s revenue was up 19.0% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.